Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

400.30 +3.03 (+0.76%)
Streaming Delayed Price Updated: 12:51 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
55 56 Next >
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
Exposures Product Safety
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Latest Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Forget the "Magnificent Seven": Buy This Stock Instead
It's hard to go wrong with this high-flying drugmaker. 
Via The Motley Fool
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Why CRISPR Stock Keeps Falling
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
Exposures Product Safety
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead. 
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment
Crispr stock rose in early trades on Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment. 
Via Investor's Business Daily
Exposures Product Safety
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
Vertex Appoints Nancy Thornberry to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
One of these stocks may be riskier than the other... 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own.
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.